A graduate of Universitas Gadjah Mada, Susanti is a young Indonesian scientist who stands as a source of pride for the nation. With a background in pharmacy and personal experience battling colorectal cancer, she has emerged as a pioneer in molecular diagnostics—bringing new hope to Indonesia’s healthcare landscape.
After completing advanced studies at the Australian National University and the University of Nottingham in the UK, Susanti founded PT PathGen Diagnostik Teknologi in 2020. Alongside her team, she launched BioColoMelt-Dx, a genetic test designed for the early detection of colorectal cancer that is accurate, fast, and affordable. The product has gained international recognition and is seen as a major breakthrough in Southeast Asia’s healthcare sector.
PathGen is now expanding its focus to include nasopharyngeal, cervical, and lung cancer diagnostics. The company also actively conducts training for medical professionals and collaborates with hospitals and research institutions both domestically and internationally.
Indonesia has gained significant advantages from Susanti’s contributions:
-
Health technology independence, reducing reliance on expensive imported diagnostic tools.
-
More equitable healthcare access, especially in underserved and remote areas.
-
Greater cost efficiency for national healthcare, through early detection that lowers late-stage treatment expenses.
-
Enhanced international reputation, with homegrown innovation now recognized on the global stage.
Through her vision of “Molecular Diagnostics for All”, Susanti has proven that local innovation can go global—saving more lives and representing a tangible contribution of Indonesian talent to the nation and the world.
By: Peter Frans Gontha